histone 英 /'hɪstəʊn/ 美 /'hɪston/
释 义 n. [生化] 组蛋白
例 句 HISTONE: Histones are crucial in the process of condensing and packing DNA within a cell’s nucleus.组蛋白：组蛋白对于凝结和进一步合成细胞核内的DNA的过程必不可少。
释 义 n. 脱乙酰酶
例 句 To reverse the memory loss, doctors inject a compound called a histone deacetylase inhibitor.为了逆转记忆遗失，医生在复合物中添加了组蛋白脱乙酰基酶抑制物。
作者： Heesun Choi
In AD, post-translational modifications (PTMs) are largely changed. Acetylation is one of the important PTMs that has a variety of biological roles such as histone modulation, metabolism, and stress response. Histone deacetylase 6 (HDAC6), which is unique among histone deacetylases because of its primary cytosolic location, deacetylates several cytosolic proteins, including α-tubulin and tau. HDAC6 is increased in the brains of patients with AD, suggesting that targeting HDAC6 could be a potential therapeutic strategy in AD. Indeed, reducing or inhibiting HDAC6 has been shown to attenuate cognitive deficits, decrease Aβ plaques in AβPPswe/PS1ΔE9 mice, and ameliorate tau pathologies in rTg4510 mice as well as primary cultured neurons. In addition, it is reported that acetylation of tau at several HDAC6-regulated sites competes with phosphorylation of tau and thus inhibits its aggregation. HDAC6 also plays an important role in the ubiquitin–proteasome system (UPS) and autophagy–lysosome system (ALS), both of which are known to be responsible for tau degradation. Because tau is a substrate of HDAC6, HDAC6 might regulate tau degradation. However, the specific mechanism by which HDAC6 inhibition causes tau degradation in AD is not yet known. Moreover, to our knowledge, there has been little or no investigation of the therapeutic effects of HDAC6 inhibition on human brain organoids or AD model animals exhibiting both Aβ and tau pathologies.